Encephalitis, Tick-Borne clinical trials
The registry lists 51 studies for Encephalitis, Tick-Borne across more than 10 countries. 9 are recruiting or about to start. 48 of them are mainly about Encephalitis, Tick-Borne (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27.
Get an email when these change. Save the Encephalitis, Tick-Borne studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Pfizer (19) · University Medical Centre Ljubljana (7) · Medical University of Vienna (3) · Novartis (3) · Sormland County Council, Sweden (2) · University Hospital, Strasbourg, France (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Institut Pasteur du Cambodge (1)
What is being tested here
Drugs under test in Encephalitis, Tick-Borne studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Doxycycline | 1 | 0 | 2 |
| Dexamethasone | 1 | 1 | 1 |
| Tick-borne encephalitis vaccine | 0 | 4 | 9 |
| Thioridazine | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 6 Encephalitis, Tick-Borne studies recruiting now, 5 (83%) set no upper age limit and 1 (17%) stop at 75 or younger. 3 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (50%) | 3 (50%) |
| 18 | 6 (100%) | 6 (100%) |
| 30 | 6 (100%) | 6 (100%) |
| 40 | 6 (100%) | 6 (100%) |
| 50 | 6 (100%) | 6 (100%) |
| 65 | 6 (100%) | 6 (100%) |
| 75 | 6 (100%) | 6 (100%) |
| 85 | 5 (83%) | 5 (83%) |
Across all 51 studies, recruiting or not: 47% stop at 75 or younger and 39% at 65; 51% take children; 2% are for women only and 0% for men only; 78% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 12, 2026.
Newly registered1
- FINtick - a Prospective Multicenter Study on Tick-borne Infections in FinlandOct 27, 2026NCT07897825
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 → or search them.
- FINtick - a Prospective Multicenter Study on Tick-borne Infections in FinlandRecruitingNCT078978251 country
- Dexamethasone in Tick-borne EncephalitisRecruitingNCT07584525Phase 31 country
- First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.Not yet recruitingNCT07377253Phase 11 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech RepublicRecruitingNCT072740461 country
- Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in FranceRecruitingNCT071912231 country
- Tick-borne Encephalitis and Borrelial Antibodies in SerumRecruitingNCT03956446Not applicable1 country
- Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne DiseasesNot yet recruitingNCT06859619Not applicable1 country
- Primary TBE Vaccination for the ElderlyNot yet recruitingNCT04573205Phase 41 country
- Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric CasesCompletedNCT056073941 country
- Tick-borne Encephalitis Virus Research in LimousinCompletedNCT059415461 country
- Fever After Tick Bite StudyWithdrawnNCT039324481 country
- Management of Tick-borne EncephalitisCompletedNCT065932491 country
- The NOrwegian Tick-borne Encephalitis StudyActive, not recruitingNCT051380551 country
- Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in ChildrenCompletedNCT00840801Phase 32 countries
- Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and OlderCompletedNCT04648241Phase 31 country
- Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization ScheduleCompletedNCT00460486Phase 31 country
- Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT RecipientsCompletedNCT01991067Phase 21 country
- Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination SchedulesCompletedNCT01562444Phase 41 country
- New Study - Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT02318069Phase 2/32 countries
- TBE Seropersistence up to 10 Years After First Booster in AdultsCompletedNCT01582698Phase 41 country
- Application of a TBE-Vaccine in Obese PersonsStatus unknownNCT04017052Phase 41 country
- Tick-borne Encephalitis and Possible Borrelial SerologyCompletedNCT039580581 country
- Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)CompletedNCT00894686Phase 43 countries
- Tick-borne Encephalitis and Positive Borrelial AntibodiesStatus unknownNCT02463942Not applicable1 country
- Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVacCompletedNCT01710189Phase 41 country
- Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)TerminatedNCT01031537Phase 21 country
- Aseptic Meningoencephalitis in SloveniaStatus unknownNCT023284691 country
- Humoral Response to Tick-borne Encephalitis Vaccine in ElderlyCompletedNCT01361776Phase 2/32 countries
- Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.CompletedNCT00161798Phase 21 country
- Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 YearsCompletedNCT00161954Phase 41 country
- Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 YearsCompletedNCT00161785Phase 41 country
- Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in ChildrenCompletedNCT001636181 country
- FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsCompletedNCT00161850Phase 22 countries
- Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 YearsCompletedNCT00161746Phase 2/31 country
- Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPURCompletedNCT00161824Phase 31 country
- Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 YearsCompletedNCT00161863Phase 33 countries
- TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)CompletedNCT00161967Phase 43 countries
- Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.CompletedNCT00161772Phase 22 countries
- TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)CompletedNCT00503529Phase 41 country
- FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsCompletedNCT00161889Phase 21 country
- FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 YearsCompletedNCT00161876Phase 31 country
- Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)CompletedNCT00163540Phase 41 country
- An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBECompletedNCT01106482Phase 41 country
- Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis VaccinationCompletedNCT00804219Phase 41 country
- Postencephalitic Symptoms After Tick Borne EncephalitisStatus unknownNCT009415901 country
- Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus VaccineStatus unknownNCT00890422Phase 22 countries
- Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five YearsCompletedNCT00452621Phase 41 country
- Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy ChildrenCompletedNCT00311441Phase 41 country
- Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy AdultsCompletedNCT00118924Phase 11 country